ATIM-02. TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA IN A PHASE 2 STUDY

ABSTRACT: Abstract For patients with WHO grade II meningioma, the two-year and five-year overall survival is 93% and 73%, respectively. Patients with malignant meningioma (grade III) have significantly worse outcomes, with five-year overall survival rates of 42%. The recurrence rate remains high with overall survival is as low as 3 years after diagnosis. The current treatment for high grade and recurrent meningioma includes maximal safe surgical resection and radiation. Tumor Treating Fields (TTFields) and Bevacizumab (BEV) have been reported to potentially show activity in recurrent and high-grade meningioma. The combination of TTFields and BEV may provide a viable treatment option for patients with recurrent and high grade meningioma. This Phase 2 Simon two-staged, non-randomized, open-label phase

SUBMITTER: Kumthekar P 

PROVIDER: S-EPMC6216118 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature